Biohaven Pharmaceutical Holding Company

Biohaven Pharmaceutical Holding Company operates as a biopharmaceutical firm dedicated to the discovery, development, and commercialization of treatments designed to improve patient lives. The company focuses its scientific efforts across several key therapeutic areas, including neuroscience, immunology, and oncology, striving to advance medical solutions that address significant unmet needs within these fields. Its approach prioritizes rigorous scientific exploration and a continuous evolution in drug discovery methodologies.

The company's trajectory has been significantly shaped by its leadership, notably Dr. Vlad Coric, who serves as Chairman and Chief Executive Officer. Dr. Coric has been instrumental in guiding Biohaven's strategic vision for over seven years, spearheading its pursuit of innovative therapies. His leadership reflects a commitment to building a company focused on addressing critical health challenges, drawing upon a background in pharmaceutical development to drive progress.

Biohaven's primary beneficiaries are patients suffering from a range of conditions within its therapeutic focus, particularly those with neurological and neuropsychiatric diseases. The company’s overarching mission is to deliver life-changing treatments, driven by the understanding that for many patients, time is of the essence. Biohaven aims to contribute meaningfully to healthier lives globally through its ongoing research and development initiatives.